Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf appetite suppression on Wegovy hasn't kicked in the way you expected, you are not alone and you are not doing anything wrong. Semaglutide works differently in different people, and the early weeks on a starter dose are often quieter than patients anticipate. The appetite-reducing effect tends to build gradually as the dose increases and your body adjusts to the medicine. Wegovy is a prescription-only medicine; a prescriber assesses whether it is suitable for you and guides any changes to your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide acts on GLP-1 receptors in the brain (particularly in the hypothalamus, which regulates hunger signals) as well as slowing the rate at which the stomach empties. The combined effect is that meals feel more filling and the urge to eat between them is reduced. That is the mechanism. But the mechanism only becomes noticeable once the medicine reaches a concentration that is meaningful for your body's particular receptor sensitivity, and that threshold varies between individuals.
At the 0.25 mg starting dose, most people feel very little. That dose is there to let your gut adapt, not to suppress appetite. The question of whether Wegovy suppresses appetite is answered clearly by the clinical trial data (it does) but the operative word is patience with the titration ladder. The STEP 1 trial, published in the New England Journal of Medicine, produced an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. That result was built over months, not days.
A less-discussed factor is caloric compensation. Some people unconsciously eat slightly more when they feel the medicine is not working, which counteracts the modest effect that is already there. Tracking what you eat for even a week or two can reveal whether the medicine is having a quiet effect you have not noticed yet.
There is real variation here, and it is worth being honest about that rather than giving a figure that sets the wrong expectation. Some people report a clear drop in hunger within 48 hours of their first dose increase. Others say the shift only registered after two or three weeks at a new level. Both experiences are consistent with how semaglutide behaves pharmacologically.
The timeline for appetite suppression with semaglutide depends partly on how quickly the medicine reaches a steady state in your system, which takes around five weeks at each dose level. So if you have recently moved from 0.5 mg to 1.0 mg, you may not feel the full effect of that increase until the fifth or sixth week. This is why prescribers follow a roughly four-weekly titration — not four weeks is enough, but four weeks is the minimum before a fair assessment.
The NHS medicines information for semaglutide notes that the dose is increased gradually over several months to the maintenance level; appetite effects follow the same curve. If you are still on a lower dose, the honest answer is that the effect you are looking for may simply not be achievable at your current level, and that is a conversation for your prescriber, not a reason to assume the medicine will not work for you.
Yes, and these are things worth knowing about. Stress and poor sleep both raise cortisol and ghrelin, the hormones that drive hunger, and they can partially override the appetite-suppressing signal that semaglutide is trying to send. If your sleep has been difficult or you have been under sustained pressure, that may explain why the expected effect feels muted.
Diet composition also matters more than people expect. Ultra-processed foods, particularly those engineered to bypass fullness signals, can undermine the natural feedback loop that semaglutide is trying to support. Thinking about what to eat on Wegovy is not about following a rigid meal plan, it is about choosing foods that work with the medicine rather than against it. Protein and fibre are particularly useful because they independently slow gastric emptying and extend the feeling of fullness.
Some medicines can interact with semaglutide's absorption or effect profile. If you are on other regular medications, your prescriber should know, it is one reason a clinical review before every repeat is genuinely useful rather than a formality. You can read more about the wider context of Wegovy and how it is used, including what to expect across the full treatment period.
The first step is to give the current dose a full, fair trial, at least four weeks, ideally closer to five. If you are genuinely not noticing any change in hunger, appetite, or the amount you are comfortable eating after that period, document it: keep brief notes on portion size and hunger levels for a week. Concrete observations are far more useful to a prescriber than a general feeling that the medicine is not doing much.
If cost is a consideration in deciding whether to continue, our Wegovy price comparison guide sets out what private treatment actually costs in the UK and what a legitimate price should include, it is worth a read before making any decisions based on price alone.
At nume, a real prescriber, not an automated system, reads your consultation the same day. If something about your response to treatment is not what you expected, that is exactly the kind of thing to raise, through the aftercare line or at your next clinical review. You can also explore the experience of having no appetite on Wegovy for context on the opposite end of the spectrum, or check our FAQs for answers to the most common questions we receive. When you are ready to speak to someone, start a free consultation with our prescribers and get a clinical view on where you are in your treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.